By comparison, ALK-rearranged NSCLC patients represent a similar sized lung cancer subgroup and have been the basis of pioneering international randomised phase 3 trials involving up to 343 patients.4–6 The main contrast between LCNEC and ALK subgroups is that the latter currently represents an easily identifiable subtype, readily diagnosed using small biopsies. This evidence concerns the gene ALK and lung cancer.